Sunday, June 09, 2024 3:51:46 PM
Non GAAP OPEX this year trending to bottom of range $290M to $310M....So let's assume $295M for full year minus $73.6M in Q1 = $221M for remainder of year.
$280M total revenue guidance for 2024 minus $52.1M in Q1 = $227.9M Revenue for remainder of 2024. This does not include any milestone payments from Fosun/Viatris.
$227.9M x 72% GMs = $164M Gross Profit for Q2 to Q4 2024.
$164M GP minus $221M non GAAP opex = $57M Non GAAP loss for remaining 3 quarters.
Now add debt paydown and Interest expenses and finance lease payments of $35M for remainder of year:
Net Interest Expense of $2.3M/qtr for next 3 quarters:
My estimate of Finance Lease pre-payments (this is for Anji and PCI manuf/Fill/finish facilities): $8M/qtr
Athyrium debt payments: $2.5M total Q3/Q4
Add in $10M to AR/AP deficit/working capital as sales grow and I have cash burn of $57M + $35M + $10M = $102M
$277M - $102M = $175M Cash to end 2024 plus any milestone payment from Fosun/Viatris = $15M and based on current Revenue projections, Revance should finish 2024 with $190M.
Assuming revenue hits $85M in Q4: $39M RHA (15% year/year increase) , $38M in Daxi Aesthetic (58% y/y revenue increase), and $8M Daxi for CD; and we should shrink cash burn to around $27M in Q4.
Revance will need $110 to $115M in quarterly revenue to get to cash flow break even. My thinking: $40M RHA, $50M Daxi Aesthetic, and $20M Daxi CD. Should be recognizing China Fosun daxi sales by 2025 first half of 2025.
When will this happen? Q2 to Q3 2025. Revance should have over $100M cash remaining despite the accelerating Athyrium loan payoff schedule.
A solid Q2 revenue increase of 15% over Q1 would get us to $60M but that means Q3 and Q4 will need to see some big revenue growth and I am not so confident they will hit their revenue guidance so I feel that $280M revenue guidance for 2024 is at risk. My rev target is $265M, and, while disappointing, I still see Fosun milestone payment and CD milestone payments in 2025 as countering the $10M higher cash burn for 2024.
Recent RVNC News
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/14/2024 08:05:00 PM
- Revance to Participate in Upcoming Investor Conferences • Business Wire • 05/28/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:33:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:08:10 PM
- Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update • Business Wire • 05/09/2024 08:06:00 PM
- Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia • Business Wire • 05/09/2024 08:05:00 PM
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 • Business Wire • 05/02/2024 08:05:00 PM
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting • Business Wire • 04/12/2024 12:00:00 PM
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/27/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:33:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:08:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/05/2024 10:00:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:34:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:33:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:44:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:33:28 PM
- Revance Announces Pricing of $100.0 Million Public Offering of Common Stock • Business Wire • 03/04/2024 02:25:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/04/2024 11:39:11 AM
- Revance Announces Proposed Public Offering of Common Stock • Business Wire • 03/04/2024 11:37:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:36:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:07:18 PM
- Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update • Business Wire • 02/28/2024 09:05:00 PM
- Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024 • Business Wire • 02/21/2024 01:01:00 PM
- Revance to Participate in Upcoming Investor Conferences • Business Wire • 02/21/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:45:13 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM